Compare TKO Group Holdings Inc (TKO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TKO Group Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? TKO Group Holdings Inc trades at $195.18 (market cap $14.24B), while State Street SPDR S&P Biotech ETF trades at $159.2. The key difference: TKO Group Holdings Inc pays a 1.6% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, TKO Group Holdings Inc nearer its low. Which is the better fit depends on your goals.
| TKO | XBI | |
|---|---|---|
Market Cap | $14.24B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $224.96 | $164.28 |
52-Week Low | $176.49 | $86.92 |
Enterprise Value | $18.60B | — |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TKO trades at $194.10, up 2.47% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed revenue growth of 18% year-over-year to $1.55 billion, though EPS of $1.34 missed estimates. The company raised full-year guidance, reflecting confidence in media rights and live events. Valuation metrics like a P/E of 68.33 appear elevated relative to earnings.
The outlook is positive given raised guidance and dominant market position in sports entertainment, but high valuation and recent earnings misses pose risks. Upside to the consensus price target of $228.17 suggests potential growth, dependent on execution of growth initiatives and macroeconomic stability.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
